IPP Bureau

Alcon launches Hydrus Microstent in India to transform glaucoma care
Alcon launches Hydrus Microstent in India to transform glaucoma care

By IPP Bureau - March 11, 2026

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes

Roche reports Phase III persevERA breast cancer trial results
Roche reports Phase III persevERA breast cancer trial results

By IPP Bureau - March 11, 2026

Giredestrant shows promise despite missing primary goal

Cirena licenses breakthrough RNA synthesis technology from CU Boulder
Cirena licenses breakthrough RNA synthesis technology from CU Boulder

By IPP Bureau - March 11, 2026

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands

Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results

By IPP Bureau - March 11, 2026

The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75

Roche shareholders back full slate of proposals, approve record dividend increase
Roche shareholders back full slate of proposals, approve record dividend increase

By IPP Bureau - March 11, 2026

Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes

Codis expands UK manufacturing with groundbreaking spray dryer
Codis expands UK manufacturing with groundbreaking spray dryer

By IPP Bureau - March 10, 2026

The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027

UK pushes space-made medicines from orbit to patients with new support package
UK pushes space-made medicines from orbit to patients with new support package

By IPP Bureau - March 10, 2026

The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth

Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
Lifecore Biomedical teams up with Indomo to advance at-home acne therapy

By IPP Bureau - March 10, 2026

Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

By IPP Bureau - March 10, 2026

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications

Frontage Laboratories expands China presence with Teddy Lab acquisition
Frontage Laboratories expands China presence with Teddy Lab acquisition

By IPP Bureau - March 10, 2026

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

By IPP Bureau - March 10, 2026

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings

Medtronic & GE HealthCare supercharge 30-year alliance with global expansion
Medtronic & GE HealthCare supercharge 30-year alliance with global expansion

By IPP Bureau - March 10, 2026

GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health

By IPP Bureau - March 10, 2026

Germany will be the first launch market

KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units

By IPP Bureau - March 10, 2026

The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US
Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

By IPP Bureau - March 10, 2026

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

Latest Stories

Interviews

Packaging